Anthropic Buys One-Employee Drug Startup Ahead of Possible IPO

By Daniel Okafor

Anthropic paid for a drug company with one employee, no website, and a mouse study. The acquisition of Mithril Medicine, closed in July and disclosed only last week, is the AI firm's boldest test yet of a claim it calls the "Pipeline-in-a-Person research model": one person using Claude can run an entire drug pipeline.

The person is Cody Tranbarger, Mithril's founder and CEO. He worked out of Atlas Venture's Kendall Square offices in Cambridge; Atlas also invested in Mithril. Tranbarger used Claude to manage contracts, logistics and experiments across 11 outside labs. He handed most other operational work to AI. The result: Mithril moved a potential treatment for two rare forms of muscular dystrophy from idea to promising results in mice in under 18 months.

Anthropic has said it hopes to have a drug enter human clinical trials in 2028.

What does the deal actually test?

The mechanism is simple to state. Drug development normally requires teams of people coordinating vendors, contracts and experiments. Mithril substituted Claude for most of that coordination layer. Anthropic's label for the model implies one individual could manage several drug programs in parallel, not just one.

Stephen Linderman, a biotech entrepreneur and Beth Israel Deaconess physician who has followed Tranbarger and Mithril, framed the deal as a demonstration project. "My read is that Mithril gives Anthropic a use-case to test and show how AI agents can streamline the process and enable a small team to manage many parallel workflows at once, challenging some of the historical assumptions of how biopharma needs to operate," Linderman wrote by email.

He tempered the enthusiasm. "I'm very optimistic about the potential for acceleration, while cautious about sweeping predictions for how quickly we will cure diseases," Linderman wrote. "We still don't understand enough about disease biology, and promising ideas need experimental validation, reliable manufacturing and clinical evidence for safety and efficacy. AI can help with those steps, but they still take time."

Why would an AI company buy a biotech?

Two reasons emerge from the record. The first is product proof. In its IPO-related stock market filing, Anthropic wrote: "We believe that AI will profoundly accelerate the rate of progress in biology and medicine, potentially curing diseases that have plagued humanity for millennia" — and added that "to build the best tools for science, our teams need firsthand experience doing scientific research and discovery."

The second is revenue. Ananya Zutshi, a local life sciences entrepreneur, noted that if Anthropic can develop and bring new medicines to market, the company gains entry into the massive pharmaceutical market — a revenue stream beyond selling AI tools.

Zutshi also argued the industry's habits invite this kind of challenge. "The combination of high regulatory hurdles, the complexity of drug development, and, frankly, a certain degree of industry jadedness can make it easy to accept conventional wisdom as fact," she wrote in an email. "But not all of those assumptions are necessarily valid, and I think AI-native or AI-forward biotechs have a real opportunity to challenge them."

How big is the bet?

The Mithril purchase is small next to Anthropic's core business. The company remains unprofitable but posted $33 billion in revenue in the first nine months of 2026 — up roughly 1,200% over the same period last year. Its initial public offering, which could happen as soon as this month, might be the largest ever, surpassing SpaceX's July IPO that raked in $86 billion.

The deal fits a Cambridge pattern. MassLive reported in January that Anthropic set up its first local outpost in Central Square. In September the company said it would lease a larger space in Kendall Square, where co-founder Daniela Amodei said Cambridge is "where some of the world's leading life science researchers are using Claude to accelerate their work." Anthropic also partners with Generate Biomedicines, a Cambridge startup using Claude to design a cell therapy that would attack tumors.

Who is running the science?

Tranbarger graduated from Amherst College and holds two graduate degrees from Harvard, including an MBA. Atlas Venture brought him in during 2024, first as an "entrepreneur-in-residence"; he began developing Mithril later that year.

He will stay inside Anthropic. "AI is poised to transform drug development," Tranbarger wrote on LinkedIn. "If we get it right, the result will be more programs, higher hit rates and broader patient impact." He said Mithril's programs will continue to progress within Anthropic, and that his new role will be to "spearhead our broader internal drug development effort."

The market will judge the model on one date: 2028, when Anthropic says it wants its first drug in human trials.